Furthermore, ASOs have shown promising efficacy in targeting Huntington's gene (HTT) for Huntington's disease (HD), targeting SOD1 and C9ORF72 for amyotrophic lateral sclerosis (ALS), and targeting MAPT (TAU) for AD [187]. Here, MAPT is linked to juvenile Huntington disease.